IL265621A - Crystalline forms of a bile acid derivative - Google Patents

Crystalline forms of a bile acid derivative

Info

Publication number
IL265621A
IL265621A IL265621A IL26562119A IL265621A IL 265621 A IL265621 A IL 265621A IL 265621 A IL265621 A IL 265621A IL 26562119 A IL26562119 A IL 26562119A IL 265621 A IL265621 A IL 265621A
Authority
IL
Israel
Prior art keywords
acid derivative
bile acid
crystalline forms
crystalline
bile
Prior art date
Application number
IL265621A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of IL265621A publication Critical patent/IL265621A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL265621A 2016-09-30 2019-03-26 Crystalline forms of a bile acid derivative IL265621A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402813P 2016-09-30 2016-09-30
PCT/US2017/054227 WO2018064441A1 (en) 2016-09-30 2017-09-29 Crystalline forms of a bile acid derivative

Publications (1)

Publication Number Publication Date
IL265621A true IL265621A (en) 2019-05-30

Family

ID=61760943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265621A IL265621A (en) 2016-09-30 2019-03-26 Crystalline forms of a bile acid derivative

Country Status (11)

Country Link
US (1) US20200024299A1 (enExample)
EP (1) EP3518937A4 (enExample)
JP (1) JP2019529481A (enExample)
KR (1) KR20190057108A (enExample)
CN (1) CN109963567A (enExample)
AU (1) AU2017336803A1 (enExample)
BR (1) BR112019006242A2 (enExample)
CA (1) CA3038534A1 (enExample)
IL (1) IL265621A (enExample)
MX (1) MX2019003684A (enExample)
WO (1) WO2018064441A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2040713T3 (da) * 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
EP2527345B1 (en) * 2006-10-16 2015-12-16 Thesan Pharmaceuticals, Inc. Therapeutic pyrazolyl thienopyridines
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) * 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
WO2014085474A1 (en) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
HUP1300504A2 (en) * 2013-08-27 2015-03-30 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sorafenib salts
EP3331896A4 (en) * 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체

Also Published As

Publication number Publication date
CN109963567A (zh) 2019-07-02
US20200024299A1 (en) 2020-01-23
EP3518937A1 (en) 2019-08-07
AU2017336803A1 (en) 2019-04-18
KR20190057108A (ko) 2019-05-27
BR112019006242A2 (pt) 2019-06-18
WO2018064441A1 (en) 2018-04-05
EP3518937A4 (en) 2020-04-29
MX2019003684A (es) 2019-08-05
CA3038534A1 (en) 2018-04-05
JP2019529481A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
IL263824A (en) Crystals in solid form in the presence of an inhibitor
ZA201903093B (en) Crystalline forms of a magl inhibitor
EP3136857A4 (en) Crystalline form of baricitinib
EP3150600A4 (en) Dihydropyrimido loop derivative as hbv inhibitor
IL259998A (en) Polymorphic crystalline forms of obeticholic acid
ZA201806444B (en) Prodrug of amino acid derivative
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
GB201522771D0 (en) Crystalline form of a phosphate derivative
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
EP3113773A4 (en) Crystalline forms of grapiprant
HUE066360T2 (hu) Eravaciklin kristályformái
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL269073A (en) Crystalline forms of obeticholic acid
EP3518937A4 (en) CRYSTALLINE FORMS OF A BILIARY ACID DERIVATIVE
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL253479A0 (en) Crystalline forms of efinconazole
IL259982A (en) Crystalline forms of thienopyrimidine compound
HUE064755T2 (hu) Alfa-halo-akrilsav-származékok átmenetifém-katalizált protodekarboxilezõdése
EP3188737A4 (en) Crystalline form of eltrombopag free acid
IL254115A0 (en) Crystalline forms of a pyrrolpyridine compound
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
IL270937A (en) Crystalline forms of saltalicib
EP3199521A4 (en) Abscisic acid derivative